Compare Ascendis Pharma A/S (ASND) vs Toyota Motor Corp (TM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Toyota Motor Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Toyota Motor Corp trades at $174.77 (market cap $206.62B). The key difference: Toyota Motor Corp is far larger — about 11.6× Ascendis Pharma A/S's market cap, and Toyota Motor Corp pays a 3.55% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TM | |
|---|---|---|
Market Cap | $17.74B | $206.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $248.29 |
52-Week Low | $163.32 | $166.50 |
Enterprise Value | $18.11B | $370.82B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Toyota Motor (TM) trades at $176.45, up 1.22% today, with a neutral technical signal and strong fundamentals including a P/E of 9.67 and three consecutive quarterly EPS beats. The company announced a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling strategic U.S. investment. Revenue grew to $48.04T in 2025, though net income dipped slightly to $4.77T, while cash flow trends show projected recovery in 2026.
TM presents a value opportunity with low valuation multiples and consistent profitability, but faces risks from competitive pressures and fluctuating margins. Analyst consensus is mixed with 37.5% buy ratings, reflecting cautious optimism amid hybrid vehicle strength and macroeconomic uncertainties. The stock's outlook hinges on execution of expansion plans and sustained demand for fuel-efficient models.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
